EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 45 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... November 3, 2020 First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma March 5, 2024 Commemorating the Contributions of Cancer Research Greats March 12, 2021 Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... February 22, 2021 Load more HOT NEWS New independent tobacco review sets roadmap for a smokefree England for... For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid...
